Codiak BioSciences Stock

codiakbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $168.37MM

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Codiak BioSciences before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Codiak BioSciences before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Codiak BioSciences’ Stock

plusminus
Can you buy Codiak BioSciences’ stock?
You can no longer buy Codiak BioSciences’ stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Codiak BioSciences’ stock?
You can no longer sell stock of Codiak BioSciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus
What is Codiak BioSciences’ stock price?
The stock price of Codiak BioSciences is $0.057 as of 4/4/23.
plusminus
What is Codiak BioSciences’ stock ticker symbol?
The ticker symbol of Codiak BioSciences is CDAK.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Team

Management Team

Douglas E. Williams, Ph.D.
President, Chief Executive Officer & Board Member
Linda C. Bain
Chief Financial Officer
Richard Brudnick
Chief Business Officer & Head of Strategy
Andrea Difabio
Chief Legal Officer

Board Members

Theo Melas-Kyriazi
Jonathan Poole
Eric S. Lander, Ph.D.
Karen Bernstein, Ph.D.
Steven Gillis, Ph.D.
Charles L. Cooney, Ph.D.
Briggs W. Morrison, M.D.
Douglas E. Williams, Ph.D.

News

Jazz, Codiak to Partner on Exosome Therapeutics for Cancer in $1B+ Collaboration
Jazz Pharmaceuticals will use Codiak BioSciences’ engEx™ precision engineering platform to research, develop and commercialize exosome therapeutics for cancer through a collaboration that could generate more than $1 billion for Codiak,
Updated on: Jun 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.